Recent studies showed that the activation of prostaglandin (PG) receptor EP1 promotes cell migration and invasion in different cancers. The aim of this study was to investigate the role of EP1 in the proliferation of osteosarcoma (OS) cells in vitro and in vivo. EP1 mRNA and protein levels were analyzed by real-time RT-PCR and Western blot, respectively in human OS cell lines MG63, OS732, U-2OS, and 143B compared to human fetal osteoblastic hFOB 1.19 cells. MG63 cells were treated with PGE 2 , EP1 specific agonist 17-PT-PGE 2 , 17-PT-PGE 2 + EP1 specific antagonist SC51089, or DMSO (control). EP1R-siRNA or a non-silencing irrelevant RNA duplex (negative control) were used for the transfection of MG63 cells, followed by PGE 2 treatment. Nude mice carrying MG63 xenografts were treated with SC51089 (2 mg/kg/day). MG63 cells/ xenografts were analyzed by MTT assay, TUNEL assay, PKC enzyme activity assay, and Western blot (EP1 and apoptotic proteins), and tumor growth/volume was evaluated in mice. EP1 levels were significantly higher in OS cells compared to osteoblasts. PGE 2 or 17-PT-PGE 2 treatment increased the proliferation and decreased the apoptosis of MG63 cells. Inhibition of EP1 by SC51089 or siRNA markedly decreased the viability of MG63 cells. Similarly, SC51089 treatment significantly inhibited MG63 cell proliferation and promoted apoptosis in vivo. The silencing of EP1 receptor by siRNA or blockade of EP1 signaling by SC51089 activated extrinsic and intrinsic apoptotic pathways both in vivo and in vitro, as evidenced by increased levels of Bax, cyt c, cleaved caspase-3, caspase-8 and caspase-9. EP1 appears to be involved in PGE 2 -induced proliferative activity of MG63 cells. Antagonizing EP1 may provide a novel therapeutic approach to the treatment of OS.
INTRODUCTION
Osteosarcoma (OS) is the most frequent type of primary (non-hematopoietic) bone tumors occurring predominantly in young adults and adolescents. At present, available treatment strategies for OS include surgical operation, radiotherapy, and chemotherapy [1, 2] . However, the prognosis of malignant OS is very poor and the 5-year overall survival (OS) is still low. The possible reasons include invasion into the surrounding tissue and/or distant organ metastasis early in tumor progression, which prevents surgical resection as the treatment option. Furthermore, malignant OS tumors are frequently resistant to all conventional chemotherapies and, in addition, chemotherapy can induce serious systemic toxicity and side effects in OS patients [3] [4] [5] . Thus, there is an urgent need to explore alternative therapeutic targets for effective OS management. Prostaglandin E2 (PGE 2 ), one of the metabolites of arachidonic acid, is a naturally occurring prostaglandin and has an important role in the regulation of physiological and pathological processes. PGE 2 exerts its biological action through binding to specific G-protein-coupled receptors (GPCRs) known as prostaglandin receptors EP1, EP2, EP3, and EP4 [6] . It is established that the activation of these receptors by PGE 2 induces different intracellular signaling pathways, which explains diverse and sometimes opposite effects of PGE 2 . The EP1 receptor is Gαq-coupled to mediate the mobilization of cytosolic Ca 2+ and activation of protein kinase C (PKC) [6, 7] . At present, the EP1 receptor has been found in various kinds of tumor cells, including breast cancer, hepatocellular carcinoma (HCC), colon cancer, and cholangiocarcinoma cells. Recent studies showed that the EP1 receptor contributes to carcinogenesis, aggressiveness, and tumor progression in a number of cancers. PGE 2 could increase survivin expression, phosphorylation of focal adhesion kinase (FAK), and enhance cell adhesion and migration in HCC cells via the EP1 receptor [8, 9] . Moreover, the upregulation of the EP1 receptor by PGE 2 promotes skin tumor progression [10, 11] . However, the pathological significance of the EP1 receptor in human OS has not been reported yet.
In the present study, we compared the expression of the EP1 receptor between several human OS cell lines and a human fetal osteoblastic cell line. Furthermore, we investigated the pathological role of EP1 in OS and the effect of EP1 on the survival of OS cells both in vivo and in vitro.
MATERIALS AND METHODS

Cell lines and culture
Human OS cell lines MG63, OS732, U-2OS, and143B and human fetal osteoblastic hFOB 1.19 cells were provided by American Type Culture Collection (ATCC, USA). The cells were cultured in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS, Gibco), 2.5 mmol/L L-glutamine (Invitrogen, Carlsbad, CA, USA), and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin) in a humidified incubator at 37°C with 5% CO 2 .
Real-time reverse transcription (RT)-PCR
The total RNA from human OS and hFOB 1.19 cells was isolated with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer' s instructions. The RT reaction was performed using the PrimeScript™ RT Master Mix (Takara, Japan) in a final volume of 10 µl containing 0.5 µg total RNA, 2 µl 5X PrimeScript buffer, 0.5 µl Oligo (dT) primer, 0.5 µl PrimeScript RT enzyme, and RNase-free water. The primers used for the amplification of EP1 were as follows: forward 5′-GAGAAGGCTACTGCGGAGGA-3′; reverse 5′-CGGCCACA AAGTCGAAATC-3′. β-actin was used as the internal control for normalization of sample amounts, with the following primers: forward 5′-TCCTCCCTG GAGAAGAGCTA-3′; reverse 5′-CCAGACAGCACTGTGTTGGC-3′. 
Cell viability by MTT assay
The viability of MG63 cells was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. MG63 cells were cultured in 96-well plates (1×10 4 cells/well) for 24 hours and treated with PGE 2 (5 μM, Cayman Chemical Co, Ann Arbor, MI, USA), EP1 specific agonist 17-PT-PGE 2 (5 μM, Cayman Chemical), or 17-PT-PGE 2 (5 μM) + EP1 specific antagonist SC51089 (2 μM, Sigma-Aldrich, St. Louis, MO, USA). The vehicle control cells were treated with 0.5% dimethyl sulfoxide (DMSO). Moreover, EP1-silenced MG63 cells and negative control MG63 cells were treated with PGE 2 (5 μM) 48 hours after transfection. Forty-eight hours after treatments, 10 µl MTT was added to each well and samples were incubated at 37°C for 4 hours. Culture medium was then replaced with an equal volume of DMSO to dissolve formazan crystals. After shaking the mixture for 10 minutes at room temperature, the absorbance of each well was determined at 490 nm using a microplate reader (BioTek, Winooski, VT, USA).
Quantification of apoptosis
Quantitative assessment of apoptotic cells in vivo and in vitro was performed by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay, according to the manufacturer' s instructions (Promega, Madison, WI, USA). Briefly, MG63 cells were seeded in 24-well plates (2×10 4 cells/well) for 24 hours and then treated with PGE 2 (5 μM), 17-PT-PGE 2 (5 μM), or 17-PT-PGE 2 (5 μM) + SC51089 (2 μM), while the vehicle control cells were treated with 0.5% DMSO. Moreover, EP1-silenced MG63 cells and negative control MG63 cells were treated with PGE 2 (5 μM) 48 hours after transfection. Forty-eight hours after treatments, 4′,6-diamidino-2-phenylindole (DAPI) and TUNEL were used for nuclear DNA staining. The cells were analyzed using confocal fluorescence microscopy (Leica, Germany). The apoptotic index was calculated as the average percentage of positive nuclei, including apoptotic bodies, divided by the total number of nuclei from five random fields at 200× magnitude.
PKC measurement MG63 cells were seeded in 24-well plates (2×10 4 cells/well) for 24 hours and then treated with PGE 2 (5 μM), 17-PT-PGE 2 (5 μM), or 17-PT-PGE 2 (5 μM) + SC51089 (2 μM), while the vehicle control cells were treated with 0.5% DMSO. Fortyeight hours after treatment, PKC assay was carried out to evaluate the activation of EP1-PKC signaling pathway using a PKC activity assay kit (Millipore, Billerica, MA, USA), according to the manufacturer' s instructions. The counts per minute (cpm) of the samples containing PKC were compared to cpm of control samples containing no enzyme.
Mice MG63 xenograft
Animal experiments were approved by the Experimental Ethics Committee of Soochow University and performed according to the institutional Guidelines for Care and Use of Laboratory Animals. Human osteosarcoma xenografts were established in 4-6 week old male nude mice (Model Animal Research Center, NanJing University, China) by subcutaneous inoculation of 5×10 7 MG63 cells into the axilla of each mouse. After tumors reached 3-5 mm in diameter, the mice were randomly divided into control and SC51089 group (2 mg/kg/day) which received oral treatment for 21 days. Tumor growth was monitored every three days for 21 days. Measurements were made using calipers, and tumor volumes were calculated as follows: volume = length × width 2 × 0.52.
Statistical analysis
The data are presented as mean ± SD. Statistical analysis was performed using SPSS for Windows, Version 15.0. (SPSS Inc., Chicago, USA). One-way analysis of variance (ANOVA) and Dunnett' s test were used for multiple comparisons. A difference was considered statistically significant when p values were less than 0.05.
RESULTS
Membrane expression of EP1 in OS cells
EP1 mRNA and protein levels were analyzed by real-time RT-PCR and Western blot, respectively in human OS cell lines MG63, OS732, U-2OS, and 143B compared to human fetal osteoblastic hFOB 1.19 cells. As seen in Figure 1A , the mRNA levels of EP1 were significantly higher in MG63, U-2OS, 143B, and OS732 cell lines compared to hFOB 1.19 cells. Similarly, the protein levels of EP1 were significantly higher in MG63, U-2OS, 143B, and OS732 cell lines compared to hFOB 1.19 [p < 0.01] (Figure 1B-C) . Moreover, the expression of EP1 was the highest in MG63 cells. Therefore, MG63 cell line was used in the subsequent experiments to elucidate the pathological role of EP1 in the development of OS.
EP1 receptor is involved in PGE 2 -induced proliferation of OS cells
To investigate the role of EP1 in the proliferation of OS cells, we first treated MG63 cells with PGE 2 or EP1 specific agonist (17-PT-PGE 2 ). As seen in Figure 2A Blockade or silencing of the EP1 receptor inhibited 17-PT-PGE 2 -induced cell proliferation of MG63 cells
To further verify the role of EP1 in the proliferation of OS cells, we blocked and silenced EP1 receptor in MG63 cells. As seen in Figure 3A , the EP1 specific antagonist SC51089 significantly blocked 17-PT-PGE 2 -induced activation of the EP1/ PKC pathway. In addition, MG63 cells exposed to 17-PT-PGE 2 + SC51089 showed a decreased proliferation and increased apoptosis compared to MG63 cells exposed to 17-PT-PGE 2 only ( Figure 3B -C, p < 0.01). To further investigate the specific role of EP1 in MG63 cell proliferation and apoptosis, MG63 cells were transfected with EP1R-siRNA. As shown in Figure 3D -G, depletion of the EP1 receptor greatly reduced the viability and increased apoptosis of MG63 cells (p < 0.01).
Silencing of the EP1 receptor activated extrinsic and intrinsic apoptotic pathways To determine whether the silencing of EP1 receptor by EP1R-siRNA was associated with the regulation of extrinsic and intrinsic apoptotic pathways, we investigated the effect of EP1 receptor depletion on the levels of apoptosis-related molecules. As shown in Figure 4 , a significant increase in the level of Bax, cytoplasmic cyt c, and cleaved caspase-3, caspase-8 and caspase-9 was observed in EP1R-siRNA-transfected MG63 cells compared to the cells transfected with irrelevant RNA duplex (p < 0.01). By contrast, the protein expression of Bcl-2 and mitochondrial cyt c was downregulated by EP1 silencing (p < 0.01).
EP1 antagonist SC51089 significantly inhibited MG63 proliferation in vivo
To further verify the pathological role of EP1 in OS, we treated nude mice carrying MG63 xenografts with the EP1 antagonist SC51089. As shown in Figure 5A -C, SC51089 treatment decreased PKC activity, reduced tumor weight, and inhibited the growth of MG63 cells in vivo. Moreover, TUNEL staining revealed that the positive area was lower in the tumor xenograft samples from SC51089 group compared to DMSOtreated control group ( Figure 5D , p < 0.01).
EP1 antagonist SC51089 regulated apoptotic molecules in MG63 transplanted mice
To determine the effect of EP1 antagonist SC51089 on the extrinsic and intrinsic apoptotic pathways in mice transplanted with MG63 cells, we analyzed the levels of apoptosis-related molecules in the tumor tissue. As shown in Figure 6 , SC51089 treatment caused a significant increase in the protein levels of Bax, cytoplasmic cyt c, and cleaved caspase 3, caspase 8 and caspase 9 in the tumor tissue from MG63 transplanted mice (p < 0.01). Moreover, SC51089 decreased the protein levels of Bcl-2 and mitochondrial cyt c in the tumor tissue (p < 0.01).
DISCUSSION
The pathway involving the EP1 receptor and its downstream molecules is a well-known signaling pathway considered to play an important role in PGE 2 -induced proliferation, growth, and migration of malignant cells. Previous studies showed that the activation of EP1 promotes migration and proliferation of HCC, skin cancer, colon cancer, and non-small cell lung cancer cells [8] [9] [10] [11] [12] [13] . This renders the EP1-mediated signaling pathway a potential target for the development of novel cancer therapeutic approaches. However, the pathological significance of the EP1 receptor in human OS is still not clear. In the current study, we investigated the effects of EP1 on the proliferation and growth of OS cells both in vitro and in vivo. We found that the expression of EP1 was significantly higher in MG63, U2OS, 143B, and OS732 compared to hFOB 1.19 cells. Moreover, the level of EP1 was significantly higher in MG63 cells compared to the other OS cells. Therefore, in the subsequent experiments, we used MG63 cells to study the pathological role of EP1 in OS development. We showed that the activation of the EP1 receptor by PGE 2 or EP1 specific agonist 17-PT-PGE 2 effectively activated the EP1/PKC signaling pathway and promoted the proliferation of MG63 cells in vitro.
On the other hand, the inactivation of the EP1 receptor by the specific antagonist SC51089 or silencing of EP1 by siRNA reduced PKC activity and promoted apoptosis in MG63 cells in vivo and in vitro. Although in the studies of Surh et al. [10, 11] BK5.EP1 transgenic mice overexpressing EP1 had a reduced tumor multiplicity after 7,12-dimethyl-benz[a]anthracene (DMBA)/12-O-Tetradecanoylphorbol-13-acetate (TPA) treatment compared to wild type mice, which was possibly due to the downregulation of PKC, the BK5.EP1 transgenic mice showed higher papilloma to carcinoma conversion rate. Using HUH-7 and HepG2 cells, Bai et al. [9] demonstrated that PGE 2 treatment increases survivin expression and that this effect is mimicked by EP1 receptor transfection or treatment with a selective EP1 agonist. Moreover, the PGE 2 -induced upregulation of survivin is blocked by a selective EP1 antagonist or siRNA against the EP1 receptor [9] . Consistent with these findings, our results showed that PGE 2 -induced activation of EP1 plays an important role in OS development. The activation of EP1, which is coupled to Gαq, by PGE 2 activates phosphatidylcholine-phospholipase C and ultimately leads to an increase in intracellular Ca 2+ and activation of PKC [14] . Recent studies found that the activation of the EP1/PKC pathway induces gene transcription and protein synthesis of several key proteins that are involved in cell migration and invasion. Briefly, signaling through the EP1 receptor activated by PGE 2 has been shown to enhance integrin expression, induce the phosphorylation and activation of FAK in cancer cells as well as induce c-Src activation, epidermal growth factor receptor (EGFR) transactivation, and cyclic adenosine monophosphate (cAMP) response element-binding (CREB) phosphorylation [7, 8, 15, 16] . Interestingly, a previous study [17] found that PGE 2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells, suggesting the effect of PGE 2 on apoptosis pathways. Apoptosis is a programmed cell death mechanism initiated by the extrinsic or intrinsic pathways [18] . In the extrinsic apoptotic pathway, cell death signals are mediated by proapoptotic death receptors (DRs) such as those belonging to tumor necrosis factor (TNF) receptor superfamily, and this pathway is characterized by the activation of caspase-8 [19] . In the intrinsic pathway, apoptosis is controlled by Bcl-2 family proteins which have either antiapoptotic (such as Bcl-2) or proapoptotic functions (such as Bax). The oligomerization of proapoptotic Bax and Bak in the mitochondrial outer membrane leads to its permeabilization and subsequent release of cyt c, followed by the conversion of procaspase-9 to active, cleaved caspase-9. Either activated caspase-8 in the extrinsic pathway or cyt c-activated caspase-9 in the intrinsic pathway may activate executioner caspase-3, resulting in apoptosis [20] . In order to understand the relationship between the EP1 receptor and extrinsic and intrinsic apoptotic pathways, we investigated the effect of depletion of the EP1 receptor by siRNA or blockade of the EP1/PKC signaling by SC51089 on apoptosis-related molecules. As expected, we found that both EP1R-siRNA and SC51089 intervention activated the extrinsic and intrinsic apoptotic pathways, which was evidenced by increased levels of Bax, cytoplasmic cyt c, and cleaved caspase 3, caspase 8 and caspase 9 in MG63 cells and MG63 transplanted mice. Our results indicate that the EP1 receptor is involved in PGE 2 -induced extrinsic and intrinsic apoptotic pathways in MG63 cells.
CONCLUSION
In the present study, we demonstrated that PGE 2 can promote proliferation and growth of MG63 cells via EP1 both in vivo and in vitro. The extrinsic and intrinsic apoptotic pathways are involved in EP1 receptor-mediated viability of MG63 cells. Our findings provide new information regarding the putative role of the EP1 receptor in the development of OS and suggest that blocking EP1 may represent a new therapeutic strategy for OS.
